Envoy Medical completes pivotal trial enrollment for fully implanted cochlear implant; raises $30M

Envoy Medical, Inc.

2026-Q1 EPS reported -$0.08 revenue$39,000

Completed enrollment of 56 patients in U.S. pivotal trial for Acclaim cochlear implant; first three patients reach 12-month endpoint.
Closed upsized public offering for $30M gross proceeds (up to $78M with warrants); led by Nantahala Capital and Broadfin Holdings.
Interim data from first 10 patients: CNC word recognition improved from 15.2% to 39.2%; no serious adverse events; 24-hour wear time.
Q1 2026 revenue $39k; R&D expense $3.6M; cash $25.3M as of March 31, 2026.
Appointed medical device veteran Chas McKhann to Board; expanded IP portfolio to 47 patents.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Envoy Medical, Inc. reported the fiscal quarter ended March 31, 2026 results: revenue $39.

Period: the fiscal quarter ended March 31, 2026
Revenue: $39
Result: reported results

Exact text from the filing

Net Revenue was $39 for the three months ended March 31, 2026.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Envoy Medical, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-26-054185

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.